Evidence map›Paper›PMID 37546770›Full record

ArticlebioRxiv : the preprint server for biology2023

Heparan sulfate promotes TRAIL-induced tumor cell apoptosis.

Yin Luo, Huanmeng Hao, Zhangjie Wang, Chihyean Ong, Robert Dutcher, Yongmei Xu, Jian Liu, Lars C Pedersen, Ding Xu

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yin LuoDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, the State University of New York, Buffalo, NY 14214, USA.
Huanmeng HaoDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, the State University of New York, Buffalo, NY 14214, USA.
Zhangjie WangDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Chihyean OngDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, the State University of New York, Buffalo, NY 14214, USA.
Robert DutcherMacromolecular Structure Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA.
Yongmei XuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Lars C PedersenGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA.
Ding XuDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, the State University of New York, Buffalo, NY 14214, USA.
University at Buffalo, State University of New York · USUniversity of North Carolina at Chapel Hill · USNational Institutes of Health · US

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI PAUL David ADAMS, Gregory L Hura · 2017 to 2026
$28.6M
In vitro synthesis of recombinant heparan sulfateR01HL094463 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN, PAWLINSKI, RAFAL L · 2009 to 2021
$5.2M
The role of heparan sulfate in cathepsin K biologyR01DE031273 · NIDCR · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI JIAN LIU, Ding Xu · 2022 to 2026
$2.7M
Development of analytical methods for glycosaminoglycans from biological sourcesR44GM142304 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI WANG, ZHANGJIE · 2022 to 2023
$2.0M
Heparan Sulfate–Osteoprotegerin Interactions in Bone RemodelingR01AR070179 · NIAMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI XU, DING · 2017 to 2021
$1.7M
A Pixel Array Detector System for Small Angle X-ray ScatteringS10OD018483 · OD · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI CLASSEN, SCOTT · 2014 to 2014
$998k
Quantitative analysis of heparan sulfate using 13C-labeled standardsR43GM142304 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI PAGADALA, VIJAYAKANTH · 2021 to 2021
$300k
NHLBI NIH HHS R01 HL094463NIAMS NIH HHS R01 AR070179NIDCR NIH HHS R01 DE031273NIGMS NIH HHS P30 GM124169NIGMS NIH HHS R43 GM142304NIGMS NIH HHS R44 GM142304NIH HHS S10 OD018483
6 · The paper itself

Abstract

TRAIL (TNF-related apoptosis-inducing ligand) is a potent inducer of tumor cell apoptosis through TRAIL receptors. While it has been previously pursued as a potential anti-tumor therapy, the enthusiasm subsided due to unsuccessful clinical trials and the fact that many tumors are resistant to TRAIL. In this report we identified heparan sulfate (HS) as an important regulator of TRAIL-induced apoptosis. TRAIL binds HS with high affinity (

Indexed as

death receptorinternalizationOligomerizationstrand swappingTNF

Identifiers

PMID37546770
PMCPMC10402122
OpenAlexW4385308202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.